WTAE – “The solution is to find an optimal tradeoff between doing something now, such as prescribing a drug off-label, or waiting until traditional clinical trials are complete,” said Derek Angus (BCHS '92), chair of Pitt Med's Department of Critical Care Medicine. “By building this one-stop solution at the point-of-care, we are rolling out an approach that can assure that every patient admitted with COVID-19 can be enrolled in the program.”
WTAE – “We don’t really know what’s the proportion of people who get the disease that don’t have any symptoms at all, what’s the proportion of people who have mild symptoms, and what’s the proportion of people who have severe symptoms requiring hospitalization,” said Mark Roberts, chair of health policy and management at Pitt Public Health.
WHYY PHILADELPHIA – Referencing the model used in recent White House briefings, Mark Roberts, HPM chair and director of the Public Health Dynamics Laboratory, said, “It’s a surprisingly accurate model. Their predictions of what today would look like three weeks ago are very good.” The model puts the U.S. about nine days away from the peak of COVID spread.
PUBLIC SOURCE - How might we come out of extreme social distancing? Mark Roberts, director of the Public Health Dynamics Lab, thinks the most interesting option might be relaxing social distancing behaviors based on the ability to know whether the person is immune to the disease or not. We could test and say you are immune and can go back to work. That would be the most accurate way of doing it.
90.5 WESA - “If nobody ever went out and nobody ever touched anybody else, this disease could not pass at all,” said HPM's Mark Roberts, director of the Public Health Dynamics Laboratory. He thinks the current restrictions on daily life need to continue for the time being. “If people went about their lives as normal, there would be tens of thousands of cases requiring hospitalization in western Pennsylvania alone.”
MEDSCAPE - In an editorial issued just days after these new guidelines, Pitt Med's Derek C. Angus (BCHS '92), who is also an HPM distinguished professor and associate editor with JAMA, and Lamontagne of Canada say these "represent an excellent first step toward optimal, evidence-informed care for patients with COVID-19.”
PENN LIVE - “There’s a substantial likelihood we are going to see a surge that might reflect the worst-case scenario,” said HPM's Jeremy Kahn, also professor of critical care medicine. “I’d be hard-pressed to think of anything as too extreme.... I'm a little skeptical this is the most efficient solution." It would be best to move less severe cases before putting critically ill patients “in an ad-hoc ICU at a dorm or hotel.”
PITTSBURGH POST-GAZETTE - FRED offers frightening predictions about what Pennsylvania residents could face with COVID-19. “These are very scary numbers, and one thing I hope to impress upon people is that this is serious,” said Mark Roberts, director of the Public Health Dynamics Lab and chair of health policy and management. “Social distancing is seriously important…. There’s hope that further action can drive that prediction downward.”
90.5 WESA – Inmaculada Hernandez (HPM ’16) said what’s concerning is that discounts are often paid directly to insurers. This means people who are un- or under-insured generally don’t benefit from the markdowns. “This is probably increasing disparities in health care access…. We are not doing a good job of protecting patients against increases in co-pays, out-of-pocket costs and certainly those that don’t have insurance.”
THE HILL - Epidemiologist Donald Burke emphasized the need to improve the scientific basis to improve readiness: the understanding of which virus groups to watch, the field capabilities to detect spillovers in remote places before they become regional outbreaks, the organizational capacities to control outbreaks before they become pandemics, plus the laboratory tools and skills to recognize known viruses speedily, to characterize new viruses alm...
NEWSWEEK - Experts said that they can’t be certain, based on the limited data there is on SARS-CoV-2 (the germ which causes COVID-19 and shouldn’t be confused with the Severe acute respiratory syndrome (SARS) virus). Donald Burke, professor of health science and policy, said he wasn’t sure, but as SARS-CoV-2 has the same kind of error correction molecular machinery as the virus that causes SARS, “its mutation rate will be slower.”
BIOPHARMA DIVE - HPM’s Walid Gellad, director of the Center for Pharmaceutical Policy and Prescribing at Pitt, said, "The paper, I think, informs discussions about how high prices really need to be in order to encourage private risk taking for gene therapies—it may be a different number than for other drugs that have less late stage involvement by academia and NIH.”
In summer 2020, I will be entering into a fellowship position in downtown Chicago with Vizient, Inc., the nation’s leading healthcare performance improvement company. Vizient has been recognized as one of the “Best Places to Work in Healthcare” (Modern Healthcare) and among “America’s Best Management Consulting Firms” (Forbes). I'm drawn by the emphasis on healthcare informatics & analytics, career development, and the breadth of projects.
TRIB LIVE - “The goal (of social distancing) is to stop or slow the spread of infectious disease,” said HPM’s Tina Hershey. Doing so, she said, slows the spread while other public health measures have time to work. “In restricting your own movements, you are going to reduce your individual risk, but you’re also reducing the risk of others who are more vulnerable,” she said.
POLITICO - “It comes back to financial incentives,” said Inmaculada Hernandez (HPM ’16), who cited her paper published in JAMA a week ago. Once biosimilars entered the market, list prices for their biologic rivals stagnated while net prices began declining. This shows brand companies were offering bigger rebates to PBMs to try to keep market share away from biosimilars.